drugset / Trial / NCT07069036

A Study to Evaluate Single and Multiple Doses of SEP-631 in Healthy Adult Volunteers

NCT07069036 ↗

Phase 1 Completed 120 enrolled Septerna, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effects of oral SEP-631 in healthy adult volunteers.

Timeline

Start
2025-07-15
Primary completion
2025-12-18
Completion
2025-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject SEP-631 Unknown — Oral

Indications

No indication recorded.